Alegbe, Tobi https://orcid.org/0000-0003-1622-0502
Harris, Bradley T. https://orcid.org/0000-0001-9585-1016
Fachal, Laura https://orcid.org/0000-0002-7256-9752
Ramirez-Navarro, Lucia
Tutert, Marcus
Krzak, Monika
Ghouraba, Mennatallah
Strickland, Michelle https://orcid.org/0000-0001-8053-400X
Ozols, Matiss
Cohen, Celeste E.
Khullar, Saniya
Khabirova, Eleonora https://orcid.org/0000-0002-5891-6789
Panousis, Nikolaos I.
Ochoa, David https://orcid.org/0000-0003-1857-278X
Wana, Noor
Hu, May Xueqi
Skelton, Jason
Ostermayer, Jasmin
Cheam, Kimberly Ai Xian https://orcid.org/0009-0005-8842-141X
Leland Taylor, D. https://orcid.org/0000-0001-6498-6970
Gu, Yong
Dawson, Claire
Thompson, Tina
Arestang, Kenneth
Nishad, Nilanga
Brezina, Biljana https://orcid.org/0000-0001-5060-5604
Caballes, Charry Queen
Garri, Wendy
Leonard, Steven
Iyer, Vivek
Parkes, Miles https://orcid.org/0000-0002-6467-0631
Wallace, Chris https://orcid.org/0000-0001-9755-1703
McIntyre, Rebecca E. https://orcid.org/0000-0001-5291-1533
Martin, Cristina Cotobal https://orcid.org/0000-0002-5877-2228
Jones, Gareth-Rhys
Raine, Tim https://orcid.org/0000-0002-5855-9873
Anderson, Carl A. https://orcid.org/0000-0003-1719-7009
Article History
Received: 24 June 2025
Accepted: 6 May 2026
First Online: 3 June 2026
Competing interests
: B.T.H. has received speaker fees from BridgeBio. C.A.A. has received research grants or consultancy/speaker fees from Genomics plc, BridgeBio, GSK and AstraZeneca. T.R. has received research/educational grants and/or speaker/consultation fees from AbbVie, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, Mylan, MSD, Novartis, Pfizer, Sandoz, Takeda and UCB. R.E.M. and. M.T. are employees of Relation Therapeutics. N.I.P. is an employee at GSK. C.W. receives funding from MSD and GSK and is a part-time employee of GSK. The other authors declare no competing interests.